Related Experiment Videos

Cardiovascular death and manic-depressive psychosis

A Weeke1, K Juel, M Vaeth

  • 1Institute of Psychiatric Demography, Aarhus Psychiatric Hospital, Risskov, Denmark.

Insights

Tricyclic antidepressant drugs (TCA) do not increase cardiovascular death risk in manic-depressive patients. Findings suggest TCAs may even reduce risks of cardiovascular disease, suicide, and other non-cancer deaths.

Area of Science:

  • Psychiatry
  • Cardiology
  • Pharmacology

Background:

  • Manic-depressive illness (bipolar disorder) is associated with increased mortality.
  • Tricyclic antidepressants (TCAs) are commonly prescribed for mood disorders.
  • Concerns exist regarding the cardiovascular safety of TCAs.

Purpose of the Study:

  • To investigate whether therapeutic doses of TCAs increase cardiovascular mortality risk in manic-depressive patients.
  • To compare cardiovascular mortality rates before and during the widespread use of TCAs.

Main Methods:

  • Retrospective cohort study using the Danish Psychiatric Central Register.
  • Inclusion of two groups of first-hospitalized manic-depressive men: pre-TCA era (1950-1956) and TCA era (1969-1976).
  • Follow-up period of approximately 4.5 years for both groups.

Main Results:

  • Relative cardiovascular mortality was 1.87 in the pre-TCA group (n=1133) and 1.53 in the TCA era group (n=2662) compared to the general population.
  • The observed rates do not support the hypothesis that TCAs increase cardiovascular mortality.
  • A potential reduction in cardiovascular disease, suicide, and other non-cancer deaths was suggested with TCA treatment.

Conclusions:

  • Tricyclic antidepressants (TCAs) do not appear to elevate cardiovascular mortality risk in individuals with manic-depressive illness.
  • TCA treatment may be associated with a reduced risk of death from cardiovascular causes, suicide, and other non-cancerous conditions.
  • Further research is warranted to confirm the potential protective effects of TCAs.

Related Concept Videos